50 results on '"Brugnara, S."'
Search Results
2. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study
3. A long meteorological series from Schaffhausen, 1794–1845
4. 507MO REGOMA-OS: A large Italian multicenter, prospective, observational study analyzing regorafenib efficacy and safety in recurrent glioblastoma patients
5. PO-1115 Proton therapy re-irradiation plus chemotherapy achieves promising results in recurrent glioblastoma
6. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort
7. EFFICACY AND TOXICITY OF DOXIL/CAELYX( D) IN PATIENTS WITH RECURRENT EPITHELIAL OVARIAN CANCER (OC)
8. P01.084 Re-irradiation in recurrent glioblastoma: proton therapy with or without chemotherapy
9. Proton Therapy Reirradiation in Difficult-to-Treat Recurrent Glioblastoma
10. Follow-up schedule based on evidence of melanoma recurrences in 200 patients, a monoinstitutional experience
11. A new somatic mutation in the coding region of KRAS gene (G48A) found in a NSCLC patient
12. Concurrent chemoradiotherapy (cCTRT) with weekly cisplatin (wCDDP) in locally advanced cervical cancer (LACC) patients (pts): a monoinstitutional experience
13. Tumor incidence analysis in contaminated site Trento North. The data of Sentieri Project
14. Neoadjuvant Chemotherapy (NC) with or without Anthracyclines in different Invasive Breast Cancer (IBC) subtypes: outcomes according to pathological complete response (pCR) and proliferation index (PI) of residual tumor (RT)
15. Assessment of clinical outcomes and prognostic factors in patients (pts) with non-small cell lung carcinoma (NSCLC) and brain metastases (BM). Results from a single institution study
16. M04 - Follow-up schedule based on evidence of melanoma recurrences in 200 patients, a monoinstitutional experience
17. 790 - A new somatic mutation in the coding region of KRAS gene (G48A) found in a NSCLC patient
18. EP-1021 SINGLE CENTRE REPORT ON TREATMENT OF ANAPLASTIC ASTROCITOMAS WITHR RADIOTHERAPY PLUS TEMOZOLAMIDE
19. Role of Ki67 labeling index (LI) in subdividing homogeneous ER-positive grading groups of early breast cancer (EBC) in distinct biologic entities.
20. Predictive factors of response to docetaxel (DOC) rechallenge (ReC) in castration-resistant prostate cancer (CRPC) patients (pts).
21. Prognostic value of positron emission tomography (PET) in patients (pts) with metastatic or locally advanced cervical cancer (CC): A monoinstitutional experience.
22. Multiple rechallenges (ReCs) with docetaxel (DOC) as an option after first-line therapy in patients (pts) with castration-resistant prostate cancer (CRPC).
23. Temozolomide (TMZ) as prophylaxis for melanoma brain metastases (BrM): Results from a phase III, multicenter study
24. Gemcitabine (G) and cisplatin (C) in a modified 3-week schedule for non-small cell lung cancer (NSCLC): Impact on hematologic toxicity and dose intensity (DI)
25. Pain after quadrantectomy and radiotherapy (QUART) for early-stage breast cancer (BC): incidence, characteristics and influence on quality of life (QL). Results from a retrospective study
26. The predictive value of computerized tomography (CT) for surgical findings in ovarian cancer patients
27. Pain after surgery for early-stage breast cancer (BC): incidence, characteristics and influence on quality of life (QL). Results from a retrospective study
28. Telomerase activity (TA) in breast cancer and its correlation with other biological and pathological parameters
29. Are p27, p21 and p53 prognostic factors in ovarian carcinoma patients?
30. Use of 5-fluorouracil, epirubicin and mitomycin C (FEM) as adjuvant therapy in node-positive, radically-resected gastric cancer patients: survey of a general hospital experience.
31. The patient's perception of her breast following irradiation (XRT) for early breast cancer (EBC)
32. Use of prevention modalities for breast cancer: A survey on 3620 self-administered questionnaires
33. P905. The influence of education on knowledge and accomplishment to breast cancer prevention modalities: data from 2889 questionnaires
34. P904. Feasibility of adjuvant chemotherapy during skin expansion in mastectomized breast cancer patients underwent immediate reconstruction
35. P916. Ocular metastases from breast cancer: a mono institutional review
36. Central nervous system failure in melanoma patients: results of a randomised, multicentre phase 3 study of temozolomide- and dacarbazine- based regimens.
37. A double-blind randomized study comparing intramuscular (i.m.) granisetron with i.m. granisetron plus dexamethasone in the prevention of delayed emesis induced by cisplatin
38. Instability of telomerase activity (TA) in breast cancer samples as a function of storage time
39. Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors.
40. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort
41. Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
42. Onset of vitiligo following targeted therapy for BRAF V600E -mutated melanoma: case report.
43. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort.
44. Treatment with combined dabrafenib and trametinib in BRAF V600E -mutated metastatic malignant melanoma: a case of long-term complete response after treatment cessation.
45. Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre.
46. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma.
47. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.
48. Fibrinogen: a novel predictor of responsiveness in metastatic melanoma patients treated with bio-chemotherapy: IMI (italian melanoma inter-group) trial.
49. Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.
50. Concurrent adjuvant chemotherapy and immediate breast reconstruction with skin expanders after mastectomy for breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.